At SABCS 2020, investigators shared current research findings and more By BCRF | January 5, 2021 Tags: SABCS 2020 Metastatic Research Up to 45 percent of patients with metastatic breast cancer develop brain metastases, and those who do have an average survival of three to 23 months. Researchers are addressing clinical challenges and exploring the biology of
Study: Factors that affect the ability to work in people with metastatic cancer Some patients who live with metastatic cancer either want or need to continue working while coping with symptoms of their disease and treatment. A recent study that looked at over 600 people with metastatic breast, prostate, colon, or lung cancer found that
Update: FDA approves new treatment for metastatic triple-negative breast cancer The FDA approved the use of sacituzumab govitecan-hizy (Trodelvy), a treatment drug for people with metastatic triple-negative breast cancer who have received at least two prior therapies for metastatic disease. (4/27/20) Read the article Printer Friendly Page This article is most relevant for: People with
‘If I don’t find something that works, I will die’ Women living with metastatic breast cancer often feel isolated and invisible in the larger breast cancer narrative.